Biogen seeks to dismiss amended product-hopping claims in US pharma case
MLex Summary: Biogen told a US federal judge that even though it’s doubled in length, plaintiffs’ second amended complaint suffers from the same flaws that led the court to dismiss the...To view the full article, register now.
Already a subscriber? Click here to view full article